Should You Invest in Bluebird Bio Right Now?
Benjamin Graham and Warren Buffett may urge investors to buy when there's blood on the streets, but even the best advice has its limitations. In the case of Bluebird Bio (NASDAQ: BLUE) stock, there's plenty of blood, but this one belongs in the "cheap for a reason" category.
Granted, it may seem overly cautious to shy away Bluebird Bio stock when it's already down substantially in December, and soon after the company garnered a regulatory approval. Nonetheless, eager investors should consider why Bluebird's stock price crashed nearly 50% not just once, but twice within the past month.
Earlier this month, Bluebird Bio's shareholders probably felt like winners as the stock had rallied from $3 in mid-November to nearly $5 for a hot minute. Then came a regulatory clearance for Bluebird Bio, which would typically spark a relief rally in the wild world of biotech stocks.
Source Fool.com
